AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19135496
Drug: SC599 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC599 vaccine 10^5 CFU
Trial: 19135496
Drug: SC599 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC599 vaccine 10^7 CFU
Trial: 19135496
Drug: SC599 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC599 vaccine
Trial: 17920547
Drug: Antigen-specific therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antigen-specific therapy targeting myelin proteins
Trial: 15239532
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily chest physiotherapy
Trial: 12575568
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese and Western medicine (TCM-WM) for over 10 months
Trial: 12575568
Drug: Non-steroidal anti-inflammatory
RxNorm normalized name: Non-steroidal anti-inflammatory agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-inflammatory and analgesic agents
Trial: 12575568
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese and Western medicine (TCM-WM)
Trial: 9591935
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice with 10 mg felodipine ER
Trial: 9591935
Drug: Control (water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (water with 10 mg felodipine ER)
Trial: 2533057
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg celiprolol daily
Trial: 2533057
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg celiprolol daily
Trial: 29137506
Drug: Labeled Cash
RxNorm normalized name: Cashew
DrugBank: Cashew (DB10653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labeled Cash Transfer with Commitment (L-CCT)
Trial: 23265698
Drug: Peanut doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut doses through the Week 44 OFCs
Trial: 16478899
Drug: 20 mg/d
RxNorm normalized name: Valtoco, 20 mg/dose nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/d of rimonabant
Trial: 15246619
Drug: RIX4414 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIX4414 vaccine (two doses at 2 and 4 months of age)
Trial: 15246619
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two doses at 2 and 4 months of age)
Trial: 9088653
Drug: Flunisolide nasal
RxNorm normalized name: flunisolide nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunisolide nasal spray 50 micrograms twice/daily (Group 1)
Trial: 9088653
Drug: Disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate (DSCG) 10.4 mg three times/day (Group 2)
Trial: 30541745
Drug: Standard combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard combination of daunorubicin and cytarabine ('7+3')
Trial: 20604812
Drug: Mandibular implant-retained
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mandibular implant-retained overdentures (MIRO) with maxillary dentures (MCD) using two implant-ball attachments (BC)
Trial: 20604812
Drug: Mandibular implant-retained
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mandibular implant-retained overdentures (MIRO) with maxillary dentures (MCD) using four implants-bar attachments (BRC)
Trial: 20604812
Drug: Mandibular implant-retained
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mandibular implant-retained overdentures (MIRO) with maxillary fixed partial dentures (MFPD) using two implant-ball attachments (BF)
Trial: 10091344
Drug: Topical ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ciprofloxacin (0.5%)
Trial: 6822143
Drug: Clonidine 0.1
RxNorm normalized name: clonidine 0.17 MG
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine 0.1 mg twice daily
Trial: 6822143
Drug: Clonidine 0.2
RxNorm normalized name: CLONIDINE 0.2MG/24HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 0.2 mg twice daily (for those not achieving blood pressure goals)
Trial: 6822143
Drug: Hydrochlorothiazide 50
RxNorm normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 50 mg twice daily (for those not achieving blood pressure goals)
Trial: 29141373
Drug: 0.08% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.08% ropivacaine and 15 μg/ml hydromorphone (H1 group)
Trial: 29141373
Drug: 0.10% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.10% ropivacaine and 15 μg/ml hydromorphone (H2 group)
Trial: 29141373
Drug: 0.12% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% ropivacaine and 15 μg/ml hydromorphone (H3 group)
Trial: 29141373
Drug: 0.12% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% ropivacaine plus 20 μg/ml hydromorphone (first 50 women)
Trial: 7493146
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (5 ml)
Trial: 29032494
Drug: Exenatide +
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide + insulin
Trial: 8408474
Drug: Insulin only
RxNorm normalized name: Isophane insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin only
Trial: 27498355
Drug: BiP 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BiP 5 mg
Trial: 27498355
Drug: BiP 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BiP 15 mg
Trial: 27498355
Drug: BiP 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BiP 1 mg
Trial: 27498355
Drug: BiP (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BiP (5 mg and 15 mg)
Trial: 16621911
Drug: Ghrelin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ghrelin infusion (5.0 pmol/kg.min) during hyperinsulinemic euglycemic clamp
Trial: 16621911
Drug: Ghrelin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ghrelin infusion (5.0 pmol/kg.min)
Trial: 10798540
Drug: LH-RH agonist
RxNorm normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LH-RH agonist monotherapy (leuprorelin acetate depot, 3.75 mg monthly)
Trial: 10798540
Drug: LH-RH agonist
RxNorm normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LH-RH agonist in combination with chlormadinone acetate (100 mg/day)
Trial: 1558340
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy plus ranitidine
Trial: 3894147
Drug: Gemeprost (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemeprost (1 mg vaginal pessary)
Trial: 29743076
Drug: Daily Mile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Mile intervention
Trial: 27238921
Drug: POD treatment
RxNorm normalized name: Senna pod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: POD treatment (scaling, root planing, and subantimicrobial dose doxycycline)
Trial: 27238921
Drug: Adherence to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence to doxycycline therapy
Trial: 19783106
Drug: Naltrexone and
RxNorm normalized name: Naltrexone and Bupropion Hydrochlorides Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone and psychosocial treatment for alcohol dependence
Trial: 19783106
Drug: Naltrexone and
RxNorm normalized name: Naltrexone and Bupropion Hydrochlorides Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone and psychosocial treatment for comorbid alcohol and cocaine dependence
Trial: 16267634
Drug: Quetiapine (589.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (589.7 mg/day)
Trial: 16267634
Drug: Risperidone (4.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (4.9 mg/day)
Trial: 12164745
Drug: UV‐B phototherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UV‐B phototherapy (3-times weekly narrowband TL‐01 UV‐B regimen)
Trial: 12164745
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (patients awaiting UV‐B therapy)
Trial: 7772441
Drug: lansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole 60 mg
Trial: 2193199
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment (1 unit.kg bw‐1.hr‐1)
Trial: 148436
Drug: Benzoyl peroxide
RxNorm normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide gels
Trial: 11015150
Drug: Gradual initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Gradual initiation of TMP/SMX suspension
Trial: 11015150
Drug: Routine initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Routine initiation of double-strength (DS; 160 mg/800 mg) tablets
Trial: 1619985
Drug: E +
RxNorm normalized name: Perle +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E + C (ephedrine 20 mg/caffeine 200 mg)
Trial: 26771947
Drug: Clinical management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical management combined with pharmacotherapy (CM+MED)
Trial: 16207425
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy with recombinant tissue‐type plasminogen activator (rtPA) intravenously
Trial: 16207425
Drug: Anticoagulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation therapy with low molecular weight heparin
Trial: 11910672
Drug: 40‐mg isoflavone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40‐mg isoflavone supplement (one tablet per day)
Trial: 2039897
Drug: Bladder retraining
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bladder retraining and terodiline 25 mg daily
Trial: 30040762
Drug: Bimanual training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimanual training with error augmentation
Trial: 30040762
Drug: Bimanual training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimanual training without error augmentation
Trial: 19846114
Drug: Guided resistance
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided resistance training twice weekly for 4 months (team GCK)
Trial: 15928801
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets (one tab/week)
Trial: 10599727
Drug: GH dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH dosage group A, 4 IU/m2 day (approximately 0.045 mg/kg x day)
Trial: 10599727
Drug: GH dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH dosage group B, first year 4 IU/m2 x day, thereafter 6 IU/m2 x day (approximately 0.0675 mg/kg/day)
Trial: 10599727
Drug: GH dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH dosage group C, first year 4 IU/m2 x day, second year 6 IU/m2 x day, thereafter 8 IU/m2 x day (approximately 0.090 mg/kg x day)
Trial: 10599727
Drug: GH dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH dosage group A
Trial: 10599727
Drug: GH dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH dosage group B
Trial: 10599727
Drug: GH dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH dosage group C
Trial: 7774515
Drug: Ramipril 2.5
RxNorm normalized name: ramipril 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 2.5 or 5 mg/day
Trial: 7774515
Drug: Ramipril 5
RxNorm normalized name: ramipril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 5 or 10 mg/day
Trial: 7774515
Drug: Ramipril with
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril with diuretics (hydrochlorothiazide or piretanide)
Trial: 27224980
Drug: TAU (Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU (Treatment as usual)
Trial: 26058405
Drug: Cold-gel packing
RxNorm normalized name: menthol Topical Gel [Cold Spot]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold-gel packing
Trial: 22882759
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of natural progesterone
Trial: 22882759
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of natural progesterone
Trial: 19803419
Drug: BNP/NT-proBNP-guided therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNP/NT-proBNP-guided therapy
Trial: 17557771
Drug: Salmeterol/fluticasone propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/fluticasone propionate (SFC) 50 microg salmeterol and 500 microg fluticasone propionate twice daily for 3 months
Trial: 17557771
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 500 microg twice daily for 3 months
Trial: 9651466
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg twice daily), clarithromycin (250 mg twice daily), and tinidazole or metronidazole (500 mg twice daily) for 1 week
Trial: 9651466
Drug: Standard metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard metronidazole and bismuth combination therapies
Trial: 7986443
Drug: Subgingival irrigation
RxNorm normalized name: DOXYCYCLINE 10% SA SUBGINGIVAL SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgingival irrigation with amine fluoride-stannous fluoride gel
Trial: 2637081
Drug: Dissolved cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dissolved cisplatin (30 mg/24 hours)
Trial: 2637081
Drug: Systemic treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic treatment with dissolved cisplatin (50 mg/die)
Trial: 25919966
Drug: Placebo (for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (for both aspirin and celecoxib)
Trial: 21306414
Drug: Linagliptin 100
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Linagliptin 100 mg
Trial: 19673817
Drug: Receptive music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receptive music therapy programs
Trial: 16495394
Drug: Denosumab (6,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (6, 14, or 30 mg every three months or 14, 60, 100, or 210 mg every six months)
Trial: 15525311
Drug: Topical bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical bupivacaine (0.25%)
Trial: 9629990
Drug: Cordaflex 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cordaflex 20 mg retard filmtablet after fasting
Trial: 9629990
Drug: Cordaflex 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cordaflex 20 mg retard filmtablet after food ingestion
Trial: 27155968
Drug: Animal-assisted activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Animal-assisted activity (AAA) with a dog, 30 min sessions, twice a week for 12 weeks
Trial: 14517494
Drug: Melagatran 0.1-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melagatran 0.1-5 mg single subcutaneous doses
Trial: 14517494
Drug: Melagatran 3
RxNorm normalized name: melagatran
DrugBank: Melagatran (DB13616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melagatran 3 mg subcutaneous doses every 12 hours for 4 days
Trial: 343913
Drug: 2alpha, 3alpha-epithio-5alpha-androstan-17beta-yl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2alpha, 3alpha-epithio-5alpha-androstan-17beta-yl 1-methoxycyclopentyl ether (mepitiostane) 10 mg b.i.d.
Trial: 343913
Drug: Fluoxymesterone 10
RxNorm normalized name: fluoxymesterone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxymesterone 10 mg b.i.d. (Control)
Trial: 27259311
Drug: Phenylephrine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (50 μg/min)
Trial: 27259311
Drug: Ephedrine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine (4 mg/min)
Trial: 24362908
Drug: Cryotherapy using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryotherapy using frozen gel gloves
Trial: 22650317
Drug: Aloe vera
RxNorm normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloe vera gel (5 mg applied topically three times daily for 3 months)
Trial: 22650317
Drug: Antioxidant capsules
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant capsules (twice daily for 3 months)
Trial: 19250006
Drug: Ginger 250
RxNorm normalized name: ginger root 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger 250 mg capsules for 4 days
Trial: 15726523
Drug: Daily subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous injection of amifostine
Trial: 15726523
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus infusions of amifostine
Trial: 15726523
Drug: Standard (once-daily)
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard (once-daily) radiation therapy alone
Trial: 15726523
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy with standard radiation therapy
Trial: 15726523
Drug: Hyperfractionated (twice-daily)
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated (twice-daily) radiation therapy plus concomitant chemotherapy
Trial: 7661347
Drug: 40‐cm2 fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40‐cm2 fentanyl patch and a 60‐cm2 placebo patch
Trial: 7661347
Drug: 60‐cm2 fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60‐cm2 fentanyl patch and a 40‐cm2 placebo patch
Trial: 3295129
Drug: Adr (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adr (60 mg/m2 IV on day 1) and DTIC (250 mg/m2 every 3 weeks)
Trial: 3295129
Drug: Adr (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adr (60 mg/m2 IV on day 1), DTIC (250 mg/m2 every 3 weeks), and Cyclophosphamide (500 mg/m2 on day 1)
Trial: 3295129
Drug: Adr (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adr (60 mg/m2 IV on day 1), DTIC (250 mg/m2 every 3 weeks), and Actinomycin D (1.2 mg/m2 on day 1)
Trial: 25641922
Drug: CLA80:20 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLA80:20 (4 g/day)
Trial: 24119523
Drug: Intralesional betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional betamethasone (1.4 mg)
Trial: 24119523
Drug: Intralesional triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional triamcinolone acetonide (8 mg)
Trial: 19148563
Drug: Risedronate treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate treatment
Trial: 16366765
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Diazepam (DZ)
Trial: 11564386
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg once daily (n = 108)
Trial: 11564386
Drug: Cerivastatin 0.3
RxNorm normalized name: cerivastatin 0.3 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin 0.3 mg once daily (n = 107)